Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV

Anixa Biosciences (NASDAQ: ANIX) announced that Chairman and CEO Dr. Amit Kumar will be interviewed on the RedChip Small Stocks, Big Money™ show airing on Bloomberg TV Saturday, May 2, 2026 at 7pm ET.

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) announced that Chairman and CEO Dr. Amit Kumar will be interviewed on the RedChip Small Stocks, Big Money™ show airing on Bloomberg TV Saturday, May 2, 2026 at 7pm ET. The interview will review the company, its capital‑efficient model, the breast cancer vaccine Phase 1 results showing protocol‑defined immune responses in 74% of participants, and ongoing positive survival data for ovarian CAR‑T therapy lira‑cel in a Phase 1 trial. Bloomberg TV reaches an estimated 73 million U.S. homes; the segment is also available online via Anixa’s website.

Argus May 1 session

+4.67% close to close Open Argus

Details

News Market Reaction – ANIX

On May 1, the day this news came out, ANIX closed 4.67% above the previous close.

Data tracked by StockTitan Argus for the May 1 session.

Market Context

This announcement highlights broader investor outreach, with Anixa’s CEO featuring on a Bloomberg TV...

Analysis

This announcement highlights broader investor outreach, with Anixa’s CEO featuring on a Bloomberg TV program reaching an estimated 73 million U.S. homes. The interview reiterates the breast cancer vaccine’s Phase 1 success, with protocol-defined immune responses in 74% of participants, and positive survival data from the ovarian cancer CAR-T program. In context, recent months have emphasized the same two programs via conferences, patents, and media appearances. Investors may watch for concrete Phase 2 trial initiations, updated CAR-T patient data, and funding moves under the existing $100,000,000 shelf registration.

Key Figures

Immune response rate: 74% of participants Bloomberg TV reach: 73 million homes Net loss: $2.565M +5 more

Immune response rate

74% of participants

Breast cancer vaccine Phase 1 trial protocol-defined immune responses

Bloomberg TV reach

73 million homes

Estimated U.S. households with Bloomberg TV access

Net loss

$2.565M

Net loss attributable to common shareholders, quarter ended Jan 31, 2026

Cash and investments

$14.202M

Cash, cash equivalents and short-term investments at Jan 31, 2026

CAR-T patients treated

13 patients

Ovarian cancer CAR-T Phase 1 dose-escalation trial

Net tangible book value

$0.46 per share

As of July 31, 2025 in S-3 shelf prospectus

Shelf capacity

$100,000,000

Maximum aggregate offering under current S-3 shelf registration

ATM proceeds

$1.625M

Capital raised via at-the-market stock offering in latest 10-Q

Historical Context

5 past events · Latest: Apr 29

5 events

1. Apr 29

   Patent issuance

   24h Move

   -4.3%

   Mexican patent No. 432748 issued, extending breast cancer vaccine IP into 2040s.

2. Apr 22

   Conference presentation

   24h Move

   +2.6%

   ISCT 2026 meeting presentation on Phase 1 ovarian cancer CAR-T therapy lira-cel.

3. Apr 09

   Investor conference

   24h Move

   +0.4%

   RedChip virtual conference talk on breast cancer vaccine and ovarian CAR-T data.

4. Apr 07

   Investor conference

   24h Move

   +3.9%

   Water Tower Research conference presentation covering strategy and key clinical updates.

5. Apr 06

   Media interview

   24h Move

   +1.6%

   Smart Money Circle interview on advancing cancer immunotherapy pipeline and trial progress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

car-t therapy, phase 1 clinical trial, breast cancer vaccine, immune responses

4 terms

car-t therapy medical

"the Company's ovarian cancer CAR-T therapy, lira-cel, exhibiting positive survival data"

CAR-T therapy is a type of medical treatment that uses a patient's own immune cells, specially modified to better recognize and attack cancer cells. For investors, it represents a significant advancement in cancer care, with the potential to transform treatment options and generate substantial demand, making companies involved in its development and production potentially valuable in the healthcare industry.

phase 1 clinical trial medical

"participants in its recently completed Phase 1 clinical trial, and the Company's ovarian"

A phase 1 clinical trial is the first stage of testing a new drug or treatment in people, typically involving a small group to assess safety, how the body handles the treatment, and appropriate dosing. For investors, phase 1 results are an early risk check — like a test drive that can reveal fatal flaws or promising signals — and they often cause big changes in a drug’s perceived value and the company’s prospects.

breast cancer vaccine medical

"the Company's breast cancer vaccine meeting primary endpoints and generating"

A breast cancer vaccine is a drug that teaches the body’s immune system to recognize and attack breast cancer cells, similar to training guard dogs to spot a specific intruder. Investors watch these vaccines because successful clinical results, regulatory approvals, or clear signs of effectiveness can transform treatment options, drive future sales, and sharply affect a developer’s valuation and stock price.

immune responses medical

"meeting primary endpoints and generating protocol-defined immune responses in 74% of"

Immune responses are the body’s reactions to something it recognizes as foreign—like a virus, vaccine, or drug—meant to detect, neutralize, or remove that threat. For investors, these reactions matter because they determine whether medical products are effective and safe; strong or targeted responses can drive approval, sales, and company value, while weak, unpredictable, or harmful responses can derail clinical programs, trigger recalls, or reduce market potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN JOSE, Calif., May 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that an interview of Chairman and CEO, Dr. Amit Kumar, will air on the RedChip Small Stocks, Big Money™ show on Bloomberg TV this Saturday, May 2, at 7pm ET. Bloomberg TV is available in an estimated 73 million homes across the U.S.

During the interview, Dr. Kumar will provide an overview of the Company and its capital efficient business model, as well as the Company's breast cancer vaccine meeting primary endpoints and generating protocol-defined immune responses in 74% of participants in its recently completed Phase 1 clinical trial, and the Company's ovarian cancer CAR-T therapy, lira-cel, exhibiting positive survival data in its ongoing Phase 1 clinical trial.

You may view the segment on Bloomberg TV (for channel information, check your local listings) or on the internet at Anixa Biosciences (ANIX): CEO on Breast Cancer Vaccine, Phase 2 Catalyst & Ovarian Cancer CAR-T Data.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-interview-to-air-on-the-redchip-small-stocks-big-money-show-on-bloomberg-tv-302759814.html

SOURCE Anixa Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will the Anixa Biosciences (ANIX) interview air on Bloomberg TV?

The interview airs Saturday, May 2, 2026 at 7:00 PM ET on Bloomberg TV and online. According to Anixa, the CEO will review the breast cancer vaccine Phase 1 results and ovarian CAR‑T updates; Bloomberg TV reaches an estimated 73 million U.S. homes.

What clinical results will Anixa (ANIX) discuss in the May 2, 2026 Bloomberg interview?

They will discuss the recently completed Phase 1 breast cancer vaccine meeting primary endpoints with 74% protocol‑defined immune responses. According to Anixa, the segment also covers positive survival data for ovarian CAR‑T lira‑cel and potential Phase 2 catalyst timing.

How can investors watch the ANIX Bloomberg interview online or on TV?

Viewers can watch on Bloomberg TV via local channel listings or stream the segment on Anixa’s website. According to Anixa, check local Bloomberg channel numbers and the company website for the posted webcast link and online access.

What does the reported 74% immune response mean for Anixa's (ANIX) breast cancer vaccine Phase 1?

The 74% figure denotes protocol‑defined immune responses observed among participants in the Phase 1 breast cancer vaccine trial. According to Anixa, the CEO will discuss these trial results, their implications, and potential next steps including Phase 2 planning.